Amarin Corporation plc
Neuroscience company reports on restructuring, financials
Published in Lab Business Week, June 13th, 2004
Revenues for the first quarter of 2004, which relate entirely to discontinued operations, were $1.0 million compared to $3.3 million for the same quarter in 2003, also entirely from discontinued operations. The first quarter 2003 revenues are after exceptional charges of $6.1 million relating to Permax inventories and deductions.
During the first quarter of 2004 and as previously reported, Amarin sold the majority of its U.S. operations to Valeant Pharmaceuticals International. This sale, which resulted in a loss in the quarter of $2.4 million, comprised...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2004-06-13)
More Articles from Lab Business Week
- Aerogen, Inc.
Respiratory disease drug firm's stockholders approve closing of $32.7M financing - AmeriPath, Inc.
Cancer diagnostics company reports financials after merger - American Oriental Bioengineering
Double-digit revenue, income growth expected by Chinese biotech firm - Amicus Therapeutics, Inc.
Drug development company raises $31M in series B financing - AmpliMed Corp.
Chemotherapy developer completes extended series A financing - Anadys Pharmaceuticals, Inc.
Hepatitis drug developer reports loss of $3.77 per share - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
